Lightchain Capital

Geneoscopy, LLC, based in Saint Louis, Missouri, specializes in developing non-invasive diagnostic tests aimed at preventing, detecting, and guiding treatment for gastrointestinal diseases, particularly colorectal cancer. Founded in 2015, the company utilizes a proprietary platform that extracts stool-derived eukaryotic RNA (seRNA) to create a multi-target RNA biomarker panel. This innovative approach allows for the identification of colorectal cancer by capturing the effects of DNA mutations associated with the disease. Geneoscopy's technology not only enhances screening compliance but also facilitates the early detection of colorectal neoplasms, ultimately aiming to reduce morbidity and mortality linked to colorectal cancer. The company is also exploring additional applications of its technology for related gastrointestinal conditions.

SimpleRose Inc. is a technology company based in Saint Louis, Missouri, that specializes in developing a prescriptive analytics platform aimed at enhancing decision-making processes in complex environments. Founded in 2018, the company's solutions focus on optimizing operations through applications such as scheduling, production planning, and portfolio optimization. By leveraging algorithmic innovations for improved numerical accuracy and speed, SimpleRose enables organizations to tackle intricate operational challenges and make informed decisions in real-time.

AI Proteins is a biotechnology company founded in 2021 and based in Boston, Massachusetts. The firm specializes in the design and engineering of synthetic mini protein therapeutics through an innovative drug discovery platform. Utilizing artificial intelligence, AI Proteins restructures protein therapeutics by creating synthetic proteins from the ground up, tailored to enhance their activity for various therapeutic applications. This approach allows for the rapid development of lead product candidates, providing clients with proteins that are cost-effective, durable, specific, and optimized for oral delivery.

NextRNA Therapeutics is a biotechnology company based in Cambridge, Massachusetts, founded in 2020. The company focuses on developing targeted therapeutics by discovering novel non-coding ribonucleic acids (ncRNAs) linked to various diseases. Utilizing an innovative discovery platform, NextRNA identifies and modulates RNA-binding proteins associated with disease functions of ncRNAs. This approach aims to disrupt the interactions between disease-related ncRNAs and their protein partners, thereby enabling medical practitioners to address and potentially cure a range of diseases.

SimpleRose Inc. is a technology company based in Saint Louis, Missouri, that specializes in developing a prescriptive analytics platform aimed at enhancing decision-making processes in complex environments. Founded in 2018, the company's solutions focus on optimizing operations through applications such as scheduling, production planning, and portfolio optimization. By leveraging algorithmic innovations for improved numerical accuracy and speed, SimpleRose enables organizations to tackle intricate operational challenges and make informed decisions in real-time.